Repurposing Tilmanocept for Cardiac Sarcoidosis (NCT07159074)

🧪 Interventions in This Study

• Tc 99m tilmanocept (DRUG)
• Tc 99m tilmanocept (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (1 Sites)

• Duke University Hospital — Durham, North Carolina

📞 Contact the Study Coordinator

Phone: (919) 681-2723

Email: ravi.karra@duke.edu

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Cardiac Sarcoidosis

• A Trial of Baricitinib in Patients With Cardiac Sarcoidosis — Palo Alto, California
• Diagnostic Utility of SGLT1/2 Inhibition to Facilitate Myocardial Glucose Suppression — Philadelphia, Pennsylvania
• Cardiac Sarcoidosis Multi-Center Prospective Cohort — Calgary, Alberta
• Cardiac Sarcoidosis Randomized Trial — New Haven, Connecticut
• Exosome-based Omic Signatures of Disease Activity in Cardiac Sarcoidosis (EXODACS) — Rochester, Minnesota

Explore by condition: All Cardiac Sarcoidosis clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.